top of page
nice_banner.jpg

Home / Information / NICE

NICE

We are recognised by NICE as an organisation to be consulted on new ALK-positive treatments.

Be empowered with ALK+ lung cancer information you can rely on 

ALK Positive UK is committed to producing reliable, accurate and up to date content reflecting the best available research evidence, and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest. 

Documents

Name

Summary of Contents

Action

Alectinib Aug 2018 (first line)

This document contains information on Alectinib for untreated ALK-positive Non-small cell lung cancer

Download

Brigatinib (after Cerit/Alect)

This webpage contains information on Brigatinib for treating ALK-positive NSCLC after Alectinib/Ceritinib

View website

Brigatinib March 2019 (after Crizotinib)

This document contains information on Brigatinib for treating ALK-positive NSCLC after Ceritinib

Download

Brigatinib Nov 2020 (first line)

This webpage summarises Brigatinib for ALk-positive Advanced NSCLC that hasn't been treated with an ALK Inhibitor

View website

Cancer Recognition & Referral

This document contains information on recognition and referral of suspected cancer

Download

Ceritinib Jan 2018 (first line)

This document contains information on Ceritinib for untreated ALK-positive Non-small cell lung cancer

Download

Ceritinib Jun 2018 (after Crizotinib)

This document contains information on Ceritinib for previously treated ALK-positive Non-small cell lung cancer

Download

Crizotinib Dec 2016 (previously treated)

This document contains information on Crizotinib for previously treated ALK-positive Advanced NSCLC

Download

Crizotinib Sept 2016 (first line)

This document contains information on Crizotinib for untreated ALK-positive Advanced NSCLC

Download

Lorlatinib Approved For 1st Line Use in Scotland (March 2022)

This webpage by Healthcare Improvement Scotland contains information on Lorlatinib being accepted for use within NHSScotland

View website

Lorlatinib May 2020 (previously treated)

This document contains information on Lorlatinib for previously treated ALK-positive Advanced NSCLC

Download

TKI
Approved
Use
Crizotinib
Sept 2016
First Line
Crizotinib
Dec 2016
After Chemotherapy
Ceritinib
Jan 2018
First Line
Ceritinib
June 2018
After Crizotinib
Alectinib
Aug 2018
First Line
Brigatinib
March 2019
After Crizotinib
Lorlatinib
May 2020
After Previous Treatment with TKI
Brigatinib
Nov 2020
First Line
NICE Relationship Graph
Image
Image

ALK Positive Lung Cancer (UK) is committed to producing reliable, accurate and up-to-date content reflecting the best available research evidence and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.

​

ALK Positive Lung Cancer (UK) is a registered charity in England and Wales ((1181171) and Scotland (SC053692).  The registered office is at 1 Ethley Drive, Raglan, Monmouthshire, NP15 2FD.

The content of this website is for information only and should not be used for the diagnosis or treatment of medical conditions.  We are unable to offer specific medical advice and, if you are worried about any symptoms, you should consult your doctor.​​

View our privacy policy HERE        View our consent policy HERE

No part of this publication may be reproduced or tansmitted in any form or by any means, electronically, mechanically or manually without permission in writing of ALK Positive Lung Cancer (UK).

bottom of page